help + privacy policy + contact us + links + home
 
About APhACareerse-CommunitiesMeetingsPublicationsJoin APhA

Advertisement


Advertisement


American 
Pharmacists 
Month

APhA CEO Blog

APhA 
Foundation



2010 International Pharmaceutical Federation PSWC and AAPS Annual 
Meeting

Print this page

FDA warns of unapproved ED ‘supplements’
Promoted for treating erectile dysfunction, products contain prescription agents, are unapproved and illegal.

FDA is warning consumers not to purchase or consume Zimaxx, Libidus, Neophase, Nasutra, Vigor-25, Actra-Rx, or 4EVERON. These products are promoted and sold on Web sites as "dietary supplements" for treating erectile dysfunction (ED) and enhancing sexual performance, but they are in fact illegal drugs that contain potentially harmful undeclared ingredients. These products have not been approved by FDA, and there is no guarantee of their safety and effectiveness, or of the purity of their ingredients, the agency noted in a news release.

FDA advises consumers who have used any of these products to discontinue use and to consult their health care provider. FDA encourages anyone experiencing ED to seek guidance from a health care provider before purchasing a product to treat this medical condition.

Chemical analysis by FDA revealed that Zimaxx contains sildenafil, the active ingredient in Viagra (Pfizer). The other products contain chemical ingredients that are analogues of either sildenafil or vardenafil (Levitra—Bayer, GlaxoSmithKline, Schering). These ingredients are not disclosed in any of the illegal products' labeling. FDA emphasized.

FDA warning letters to the firms marketing these products state that the products are illegal drugs based on claims made for the products or their ingredients. The letters also state that the products' labeling is false and misleading because it fails to disclose the presence of the chemical ingredients or the potential adverse effects associated with the products' consumption. FDA instructed agency staff to stop the importation of Libidus, and the agency recently stopped a shipment of 4EVERON from entering the United States. Based on responses to these actions, FDA may take additional enforcement steps.


Web links

Related resources on www.pharmacist.com

Contact the writer: L. Michael Posey, BPharm, Pharmacy Today

Posted July 13, 2006, 4:45 pm EDT